Abstract:Background: Epigenetic regulation has been verified as a key mechanism in tumorigenesis. SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase, is a promising epigenetic therapeutic target and is overexpressed in numerous human tumors. SMYD3 can promote oncogenic progression by methylating lysines to integrate cytoplasmic kinase signaling cascades or by methylating histone lysines to regulate specific gene transcription. However, the exact role of SMYD3 in the progression of ovarian cancer is still unknown. Methods: Immunohistochemistry was employed to test SMYD3 expression in ovarian cancer tissues from clinical patients. CCK-8 assay, Real-time cell analysis (RTCA), colony formation assay, cell cycle and apoptosis tested by Flow cytometer were employed to test the effects of SMYD3 on cell proliferation and apoptosis in ovarian cancer cell lines. A PCR array was used to identify the downstream targets of SMYD3. And, PCR and Western blot were used to verify their expression. The binding of SMYD3 on the promoter of target genes were tested by ChIP assays. We also use nude mice subcutaneous tumor model and patient-derived xenograft (PDX) model to investigate the tumor promotive function of SMYD3 in vivo. Results: SMYD3 expression was higher in ovarian cancer tissues and cell lines than in normal ovarian epithelial tissue and human ovarian surface epithelial cells (HOSEpiC). After silencing SMYD3, the proliferation of ovarian cancer cells was significantly inhibited in vitro. In addition, the SMYD3-specific small-molecule inhibitor BCI-121 suppressed ovarian cancer cell proliferation. Downregulation of SMYD3 led to S phase arrest and increased the cell apoptosis rate. Furthermore, a PCR array revealed that SMYD3 knockdown caused the upregulation of the cyclin-dependent kinase (CDK) inhibitors CDKN2A (p16INK4), CDKN2B (p15INK4B), CDKN3 and CDC25A, which may be responsible for the S phase arrest. In addition, the upregulation of CD40LG and downregulation of BIRC3 may explain the increased cell apoptosis rate after silencing SMYD3. We also discovered that SMYD3 bound on the promoter of CDKN2A and down-regulated its expression by triple-methylating H4K20. In addition, SMYD3 bound on the promoter of BIRC3 and up-regulated its expression by triple-methylating H3K4. Finally, knocking down SMYD3 could inhibit ovarian cancer growth in nude mice subcutaneous tumor model and PDX model. Conclusion: Our results demonstrated that SMYD3 was overexpressed in ovarian cancer and contributes to the regulation of tumor proliferation and apoptosis via SMYD3-H4K20me3-CDKN2A pathway and SMYD3-H3K4me3-BIRC3 pathway. Thus, SMYD3 is a promising epigenetic therapeutic target for ovarian cancer.

SUV39H1-Mediated DNMT1 is Involved in the Epigenetic Regulation of Smad3 in Cervical Cancer.

SUV39H1-DNMT3A-mediated Epigenetic Regulation of Tim-3 and Galectin-9 in the Cervical Cancer

Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells

Mir-182 Induces Cervical Cancer Cell Apoptosis Through Inhibiting the Expression of DNMT3a.

Methylation-mediated silencing of EDN3 promotes cervical cancer proliferation, migration and invasion

DNA methylation regulated microRNAs in human cervical cancer

Methylation-mediated silencing of <i>EDN3</i> promotes cervical cancer proliferation, migration and invasion

An essential role for DNA methyltransferase 3a in melanoma tumorigenesis

Exploration of Tumor-Suppressive Micrornas Silenced by DNA Hypermethylation in Cervical Cancer.

N<SUP>6</SUP>-Methyladenosine Associated Silencing of miR-193b Promotes Cervical Cancer Aggressiveness by Targeting CCND1

Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20

Mir-375 Is Epigenetically Downregulated By Hpv-16 E6 Mediated Dnmt1 Upregulation And Modulates Emt Of Cervical Cancer Cells By Suppressing Lncrna Malat1

DNA methylation of miR-138 regulates cell proliferation and EMT in cervical cancer by targeting EZH2

RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer

TET1 inhibits the migration and invasion of cervical cancer cells by regulating autophagy

SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter.

SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion

SMG1 Acts As a Novel Potential Tumor Suppressor with Epigenetic Inactivation in Acute Myeloid Leukemia.

Mesenchymal Stem Cell-Derived Extracellular Vesicles Alleviate Cervical Cancer by Delivering Microrna-331-3p to Reduce LIM Zinc Finger Domain Containing 2 Methylation in Tumor Cells.

MRVI1 and NTRK3 Are Potential Tumor Suppressor Genes Commonly Inactivated by DNA Methylation in Cervical Cancer

Deregulation Between Mir-29B/c and DNMT3A is Associated with Epigenetic Silencing of the CDH1 Gene, Affecting Cell Migration and Invasion in Gastric Cancer